Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor Microenvironment Modulation via Proinflammatory Cytokine Induction and Enhanced Immune Infiltration (TME Modulation)
- Target
- TME Modulation
- Molecular classification
- Cytokine, Immunomodulator, Chemokine, Growth factor
01
Overview
This target focuses on modulating the tumor microenvironment (TME) by inducing proinflammatory cytokines and enhancing the infiltration of immune cells, particularly cytotoxic T lymphocytes (CTLs). The goal is to convert "cold" tumors, which are immunologically inactive, into "hot" tumors that are more responsive to immunotherapy. This approach leverages the complex role of inflammatory cytokines, carefully balancing their potential to promote tumor progression with their ability to mediate effective anti-tumor immune responses. Therapeutic strategies include checkpoint inhibitors, cytokine therapies, oncolytic viruses, and combinations of chemotherapy and vaccination.
- Other names
- Tumor microenvironment remodelingInflammation-mediated immunotherapyTME inflammation inductionImmune infiltration enhancement
02
Mechanism of action
Induction of proinflammatory cytokines and chemokines to promote immune cell infiltration and activation within the tumor microenvironment, leading to enhanced anti-tumor immunity.
03
Biological functions
Immune responseInflammationCell signalingCell recruitmentAntigen presentationT cell activationApoptosis
04
Disease associations
CancerImmunotherapy resistanceInflammation-associated diseases
05
Safety considerations
Cytokine release syndrome (CRS)AutoimmunityExacerbation of pre-existing inflammatory conditionsOn-target/off-tumor toxicityDevelopment of resistance mechanismsPotential for promoting tumor growth in specific contextsExcessive inflammation leading to tissue damage
06
Interacting drugs
Checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA-4)
6 more in the full profile.
07
Biomarkers
Tumor-infiltrating lymphocytes (TILs)PD-L1 expressionMicrosatellite instability (MSI)Tumor mutational burden (TMB)Cytokine levels (e.g., IFN-gamma, TNF-alpha, IL-6, IL-1beta)Expression of immune checkpoint molecules (e.g., PD-1, CTLA-4)
Beyond the preview
Go deeper on Tumor Microenvironment Modulation via Proinflammatory Cytokine Induction and Enhanced Immune Infiltration (TME Modulation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor Microenvironment Modulation via Proinflammatory Cytokine Induction and Enhanced Immune Infiltration (TME Modulation).